Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095784 · ClinicalTrials.gov registry record · Phase 2
Decitabine in Treating Patients With Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 14
- Study locations
NCT00095784 is a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (82% lower). The trial reports 14 study locations across 6 states.
The verdict
NCT00095784, a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.
Conditions Studied
Interventions
- DRUG Decitabine
- OTHER Laboratory Biomarker Analysis
Study Locations (14)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Loyola University Medical Center - Maywood
- Illinois CancerCare-Peoria - Peoria
- Central Illinois Hematology Oncology Center - Springfield
- Southern Illinois University School of Medicine - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
- Northern Indiana Cancer Research Consortium - South Bend
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Michigan
- Oncology Care Associates PLLC - Saint Joseph
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-09-29 |
| Est. Completion | 2026-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095784
The ClinicalTrials.gov registry entry for NCT00095784 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (82% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Decitabine is the first listed.
NCT00095784 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT00095784 about?
NCT00095784 is a clinical study titled "Decitabine in Treating Patients With Myelofibrosis". This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of ...
What is the current status of trial NCT00095784?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2004-09-29. Estimated completion is 2026-02-22.
What conditions does trial NCT00095784 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Secondary Myelofibrosis.
What interventions are being tested in trial NCT00095784?
The interventions under investigation include: Decitabine (DRUG), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT00095784?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00095784 being conducted?
This trial has 14 study locations across Illinois, Indiana, Maryland, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.